Celgene quarterly profit beats on Revlimid demand

Celgene quarterly profit beats on Revlimid demand


U.S. biotechnology company Celgene Corp reported lower-than-expected sales, hurt in part by soft demand for its psoriasis treatment even as sales of its flagship drug Revlimid beat estimates. The company's cancer treatment Abraxane generated sales of $236 million and its psoriasis drug Otezla brought in $242 million.



from Biotech News